WEE1 + low-intensity chemotherapy or HMA (e.g., adavosertib + decitabine) achieved remissions in heavily pretreated AML, with schedule-dependent myelosuppression (Garcia-Manero et al., 2024a). The gene discussed is WEE1; the disease is acute myeloid leukemia.